Business Context and Reporting Period
This Form 8-K is filed by Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) on April 15, 2026. The report addresses a significant delay in the filing of the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the status of the financial reporting process rather than the financial results themselves.
Material Changes and Events
- Delayed Filing: The Company previously filed a Form 12b-25 on March 31, 2026, notifying the SEC of an inability to file the 2025 Form 10-K within the prescribed timeframe.
- Extension Expiration: The Company now expects it will not be able to file the Form 10-K within the 15-calendar-day extension period provided under Rule 12b-25.
- Cause of Delay: The delay is attributed to the continued preparation of fourth-quarter and full-year financial statements and the additional time required for the independent registered public accounting firm to complete audit procedures.
Outlook, Risks, and Management Commentary
- Listing Compliance Risk: The Company anticipates receiving a notice from NYSE American indicating non-compliance with continued listing requirements due to the late filing.
- Remediation Plan: The Company expects to submit a plan to regain compliance with listing standards within the period provided by the exchange.
- Projected Filing Date: Management expects to file the Form 10-K by April 30, 2026, though they explicitly state there can be no assurance this date will be met.
Investor Verification Checklist
- Verify the receipt of any official notice from NYSE American regarding delisting or compliance plans.
- Monitor the Company's website and SEC filings for the actual submission date of the Form 10-K for the year ended December 31, 2025.
- Review the upcoming Form 10-K for details on the audit scope and any material weaknesses in internal controls that may have contributed to the delay.
- Confirm whether the Company has elected to use the extended transition period for emerging growth company accounting standards.